Security National Bank of Sioux City Iowa IA Has $724,000 Position in Teva Pharmaceutical Industries Limited (TEVA)

Security National Bank of Sioux City Iowa IA increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,788 shares of the company’s stock after buying an additional 87 shares during the period. Security National Bank of Sioux City Iowa IA’s holdings in Teva Pharmaceutical Industries Limited were worth $724,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. San Francisco Sentry Investment Group CA bought a new position in Teva Pharmaceutical Industries Limited in the 2nd quarter worth approximately $106,000. Kistler Tiffany Companies LLC boosted its holdings in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares during the period. Bronfman E.L. Rothschild L.P. boosted its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares during the period. FNY Managed Accounts LLC bought a new position in Teva Pharmaceutical Industries Limited in the 1st quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. boosted its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the period. 56.75% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Security National Bank of Sioux City Iowa IA Has $724,000 Position in Teva Pharmaceutical Industries Limited (TEVA)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/10/10/security-national-bank-of-sioux-city-iowa-ia-has-724000-position-in-teva-pharmaceutical-industries-limited-teva.html.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 0.13% during trading on Tuesday, reaching $15.75. 6,831,056 shares of the company were exchanged. The stock’s 50 day moving average is $16.87 and its 200 day moving average is $26.56. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $45.14. The company’s market capitalization is $16.00 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.25 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.26 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 2.16%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

Several research firms recently commented on TEVA. Royal Bank Of Canada cut their price objective on shares of Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating for the company in a report on Monday, September 18th. Wells Fargo & Company reaffirmed a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, October 5th. Credit Suisse Group set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday, August 3rd. Maxim Group reaffirmed a “hold” rating and issued a $15.50 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, September 14th. Finally, Cantor Fitzgerald set a $31.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. Five research analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and a consensus target price of $27.63.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit